Navigation Links
Isolagen Inc. Promotes Declan Daly to Chief Executive Officer (CEO)
Date:1/8/2008

Nicholas L. Teti, Jr. will continue as Chairman of the Board

EXTON, Pa., Jan. 8 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that the Board of Directors has named Declan Daly as Chief Executive Officer (CEO) of the Company. Mr. Daly will continue as Chief Financial Officer (CFO) of Isolagen Inc. for a period of time. Former Chief Executive Officer Nicholas L. Teti, Jr. will continue to serve as Chairman of the Board of Directors and as a consultant to Isolagen, but has resigned as President and CEO to pursue other interests.

"I have worked with Declan for many years and feel strongly that he has the financial and business expertise to lead Isolagen during this important time in the Company's lifecycle and is the right guy for the job," said Nicholas L. Teti, Jr., Chairman of Isolagen, Inc. "I am proud of the progress we have made at Isolagen over the past 20 months, particularly in advancing our clinical development program for the Isolagen(R) Therapy. Declan provides the continuity to sustain that progress and other opportunities as they relate to the Company. I plan to remain invested and active in the strategic oversight and future of the Company as Chairman of the Board of Directors."

Mr. Daly, 45, joined Isolagen as CFO and Executive Vice President - Europe in June 2006, and was promoted to COO and CFO in June of 2007. Prior to joining Isolagen, Mr. Daly spent more than seven years with Inamed Corporation and most recently served as the CFO of Inamed. Prior, Mr. Daly served as Inamed's Senior Vice President, Corporate Controller and Principal Accounting Officer, and previously as Vice President of Finance & Administration of Inamed International Corp. based in Europe. Mr. Daly holds a BA in Management Science and Industrial Systems Studies from Trinity College in Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

The Company has filed a Form 8-K dated January 8, 2008 with further information regarding the above matters.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen(TM), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
2. Isolagen Modifies Ongoing Clinical Program for Acne Scars
3. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
4. Isolagen, Inc. Postpones Annual Meeting
5. Therap Services Promotes Allison Dudo to Assistant Director of Training
6. FOXO factor promotes survival of oxygen-deprived cancer cells
7. Ratcliff Promotes 11 Staff Members
8. The HealthCentral Networks MyDiabetesCentral.com Promotes Awareness of Diabetes
9. Health Secretary Promotes Awareness of Diabetes, Urges Healthy Habits
10. Lifespring Health Promotes Health and Fitness by Sponsoring Silicon Valley Marathon on November 3rd and 4th
11. AvMed Promotes Kirk Cianciolo to Senior Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five ... genders. And the need for advanced services is growing. , Project WE vs ... program, in collaboration with their non-profit partners in their fight against cancer and in ...
(Date:2/26/2017)... New York (PRWEB) , ... February 26, 2017 ... ... baby products for wholesale distribution in North America, today announced it would be ... sites. The company, which prides itself on crafting quality and unique baby clothing/feeding ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in persons with a specific LRRK2 mutation, according to a study released today ... have provided evidence of a link between pesticides and incidence of sporadic PD ...
(Date:2/24/2017)... Princeton, NJ (PRWEB) , ... February 24, 2017 ... ... organization that provides business development, education, networking and recognition opportunities as well as ... at Bell Works in Holmdel, NJ on February 23. The Council's Innovation ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... SILVER SPRING, Md. , Feb. 23, 2017 ... today allowed marketing of the PhenoTest BC Kit, ... first test to identify organisms that cause bloodstream ... organism is likely to respond to (antibiotic sensitivity). ... it takes to provide this important information, which ...
(Date:2/24/2017)... Australie, le 24 février 2017 ITL Limited, ( ASX : ... innovante, est ravie d,annoncer les excellents résultats semestriels clos ... précédente correspondante. Une présentation complète « Résultats et mise à ... ici . Faits marquants ... (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology: